利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.019 秒)

    Method for the detection, preparation and depletion of CD4+ t lymphocytes
    5.
    发明授权
    Method for the detection, preparation and depletion of CD4+ t lymphocytes 有权

    公开(公告)号：US11226332B2

    公开(公告)日：2022-01-18

    申请号：US16507133

    申请日：2019-07-10

    申请人： IMCYSE SA

    发明人： Jean-Marie Saint-Remy ,  Vincent Carlier ,  Luc Vander Elst

    IPC分类号： G01N33/569 ,  C07K14/73 ,  C07K14/725 ,  C07K17/14 ,  G01N33/50 ,  C07K14/74 ,  A61K39/00

    摘要： The present invention relates an in vitro method for detecting class II restricted CD4+ T cells in a sample. Herein a sample is contacted with an isolated complex of an MHC class II molecule and a peptide. This peptide comprises an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. CD4+ T cells are detected by measuring the binding of the complex with cells in the sample, wherein the binding of the complex to a cell is indicative for the presence of CD4+ T cells in the sample. The present invention further relates to an isolated complex of an MHC Class II molecule and a peptide comprising an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif.

    Animal models for evaluating pharmaceutical compounds
    6.
    发明授权
    Animal models for evaluating pharmaceutical compounds 有权

    公开(公告)号：US10729791B2

    公开(公告)日：2020-08-04

    申请号：US15151868

    申请日：2016-05-11

    申请人： ImCyse SA

    发明人： Jean-Marie Saint-Remy ,  Luc Vander Elst ,  Vincent Carlier

    IPC分类号： A61K49/00 ,  G01N33/50 ,  A01K67/027

    摘要： The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.